

Mohsen Sadatsafavi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2595579/publications.pdf>

Version: 2024-02-01

348
papers

22,021
citations

22153

59
h-index

10734

138
g-index

363
all docs

363
docs citations

363
times ranked

20371
citing authors

#	ARTICLE	IF	CITATIONS
1	Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. <i>New England Journal of Medicine</i> , 2014, 371, 1198-1207.	27.0	1,807
2	Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 2486-2496.	27.0	1,253
3	Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. <i>Arthritis and Rheumatism</i> , 2008, 59, 1690-1697.	6.7	1,181
4	Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. <i>Lancet, The</i> , 2010, 376, 1838-1845.	13.7	1,098
5	Benralizumab, an anti-interleukin-5 receptor $\hat{\pm}$ monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2016, 388, 2128-2141.	13.7	1,070
6	Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting $\hat{\pm}$ 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2016, 388, 2115-2127.	13.7	1,050
7	Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1524-1529.	0.9	718
8	Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses. <i>New England Journal of Medicine</i> , 2014, 370, 2102-2110.	27.0	668
9	Economic burden of asthma: a systematic review. <i>BMC Pulmonary Medicine</i> , 2009, 9, 24.	2.0	580
10	Inhaled Combined Budesonide $\hat{\pm}$ Formoterol as Needed in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 1865-1876.	27.0	453
11	Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>Lancet Respiratory Medicine, the</i> , 2015, 3, 631-639.	10.7	425
12	As-Needed Budesonide $\hat{\pm}$ Formoterol versus Maintenance Budesonide in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 1877-1887.	27.0	368
13	Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2554-2560.	2.8	357
14	Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2009, 4, e6914.	2.5	346
15	Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 269.	7.4	336
16	Overdiagnosis of asthma in obese and nonobese adults. <i>Cmaj</i> , 2008, 179, 1121-1131.	2.0	335
17	GINA 2019: a fundamental change in asthma management. <i>European Respiratory Journal</i> , 2019, 53, 1901046.	6.7	277
18	Associations of Ambient Air Pollution with Chronic Obstructive Pulmonary Disease Hospitalization and Mortality. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 721-727.	5.6	234

#	ARTICLE	IF	CITATIONS
19	Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. <i>Lancet Respiratory Medicine</i> , 2018, 6, 51-64.	10.7	220
20	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 46-59.	10.7	216
21	Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, e56-e69.	5.6	202
22	Asthma Control in Canada Remains Suboptimal: The Reality of Asthma Control (TRAC) Study. <i>Canadian Respiratory Journal</i> , 2006, 13, 253-259.	1.6	187
23	Validity and reliability of a new food frequency questionnaire compared to 24-h recalls and biochemical measurements: pilot phase of Golestan cohort study of esophageal cancer. <i>European Journal of Clinical Nutrition</i> , 2006, 60, 971-977.	2.9	181
24	Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study. <i>Thorax</i> , 2015, 70, 822-829.	5.6	178
25	The Projected Economic and Health Burden of Uncontrolled Asthma in the United States. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1102-1112.	5.6	178
26	Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. <i>European Respiratory Journal</i> , 2018, 52, 1800936.	6.7	173
27	Adult Asthma Consensus Guidelines Update 2003. <i>Canadian Respiratory Journal</i> , 2004, 11, 9A-18A.	1.6	171
28	Canadian Thoracic Society Asthma Management Continuum – 2010 Consensus Summary for Children Six Years of Age and Over, and Adults. <i>Canadian Respiratory Journal</i> , 2010, 17, 15-24.	1.6	163
29	The global economic burden of asthma and chronic obstructive pulmonary disease. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 11-23.	1.2	163
30	Cost-effectiveness of Continuous Positive Airway Pressure Therapy for Moderate to Severe Obstructive Sleep Apnea/Hypopnea. <i>Archives of Internal Medicine</i> , 2006, 166, 977.	3.8	131
31	Statins in COPD. <i>Chest</i> , 2009, 136, 734-743.	0.8	125
32	Acetaminophen Use and the Risk of Asthma in Children and Adults. <i>Chest</i> , 2009, 136, 1316-1323.	0.8	124
33	Direct Health Care Costs Associated with Asthma in British Columbia. <i>Canadian Respiratory Journal</i> , 2010, 17, 74-80.	1.6	122
34	Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1051-1059.	2.9	122
35	Obesity and hypertension in an Iranian cohort study; Iranian women experience higher rates of obesity and hypertension than American women. <i>BMC Public Health</i> , 2006, 6, 158.	2.9	110
36	Progression from Asthma to Chronic Obstructive Pulmonary Disease. Is Air Pollution a Risk Factor?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 429-438.	5.6	110

#	ARTICLE	IF	CITATIONS
37	Undiagnosed Chronic Obstructive Pulmonary Disease Contributes to the Burden of Health Care Use. Data from the CanCOLD Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 285-298.	5.6	110
38	Eosinophilic and Noneosinophilic Asthma. <i>Chest</i> , 2021, 160, 814-830.	0.8	109
39	Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. <i>Clinical Therapeutics</i> , 2019, 41, 2041-2056.e5.	2.5	102
40	Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 568-576.	10.7	99
41	The Projected Epidemic of Chronic Obstructive Pulmonary Disease Hospitalizations over the Next 15 Years. A Population-based Perspective. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 287-291.	5.6	98
42	Probabilistic Markov Model to Assess the Cost-Effectiveness of Bronchodilator Therapy in COPD Patients in Different Countries. <i>Value in Health</i> , 2005, 8, 32-46.	0.3	95
43	Health literacy in chronic disease management: a matter of interaction. <i>Journal of Clinical Epidemiology</i> , 2018, 102, 134-138.	5.0	95
44	Sputum Microbiome Is Associated with 1-Year Mortality after Chronic Obstructive Pulmonary Disease Hospitalizations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1205-1213.	5.6	95
45	Pediatric thyroid fine-needle aspiration cytology: a meta-analysis. <i>Journal of Pediatric Surgery</i> , 2009, 44, 2184-2191.	1.6	92
46	TNF \pm antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. <i>Thorax</i> , 2013, 68, 142-148.	5.6	83
47	The CONCEPT trial: A 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. <i>Clinical Therapeutics</i> , 2005, 27, 393-406.	2.5	81
48	Artificial Intelligence/Machine Learning in Respiratory Medicine and Potential Role in Asthma and COPD Diagnosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2255-2261.	3.8	76
49	Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3997-4004.	3.8	74
50	The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1013-1021.	10.7	72
51	Discordance in diagnosis of osteoporosis using spine and hip bone densitometry. <i>BMC Endocrine Disorders</i> , 2005, 5, 3.	2.2	71
52	Asthma Worsenings: Approaches to Prevention and Management from the Asthma Worsenings Working Group. <i>Canadian Respiratory Journal</i> , 2008, 15, 1B-19B.	1.6	71
53	Health-Related Quality of Life Trajectories Among Adults With Tuberculosis. <i>Chest</i> , 2008, 133, 396-403.	0.8	70
54	Validation and Utility Testing of Clinical Prediction Models. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 235.	7.4	70

#	ARTICLE	IF	CITATIONS
55	The Preventable Burden of Productivity Loss Due to Suboptimal Asthma Control. <i>Chest</i> , 2014, 145, 787-793.	0.8	68
56	Ten-Year Trends in Direct Costs of COPD. <i>Chest</i> , 2015, 148, 640-646.	0.8	66
57	The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. <i>Quality of Life Research</i> , 2008, 17, 453-462.	3.1	64
58	Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0166745.	2.5	63
59	Safety and Clinical Effectiveness of Midazolam versus Propofol for Procedural Sedation in the Emergency Department: A Systematic Review. <i>Academic Emergency Medicine</i> , 2008, 15, 1-8.	1.8	62
60	Health State Utilities in Latent and Active Tuberculosis. <i>Value in Health</i> , 2008, 11, 1154-1161.	0.3	62
61	The impact of inappropriate use of short acting beta agonists in asthma. <i>Respiratory Medicine</i> , 2017, 131, 135-140.	2.9	61
62	Secular decreases in fracture rates 1986–2006 for Manitoba, Canada: a population-based analysis. <i>Osteoporosis International</i> , 2011, 22, 2137-2143.	3.1	59
63	Effectiveness of Educational Interventions on Asthma Self-Management in Punjabi and Chinese Asthma Patients: A Randomized Controlled Trial. <i>Journal of Asthma</i> , 2012, 49, 542-551.	1.7	59
64	Trends in Asthma-Related Direct Medical Costs from 2002 to 2007 in British Columbia, Canada: A Population Based-Cohort Study. <i>PLoS ONE</i> , 2012, 7, e50949.	2.5	59
65	Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 914-922.	2.9	58
66	Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. <i>European Respiratory Journal</i> , 2022, 60, 2102571.	6.7	57
67	Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma. <i>PLoS ONE</i> , 2016, 11, e0146003.	2.5	56
68	A Randomised Controlled Trial of High Dose, Inhaled Budesonide Versus Oral Prednisone in Patients Discharged from the Emergency Department following an Acute Asthma Exacerbation. <i>Canadian Respiratory Journal</i> , 2000, 7, 61-67.	1.6	54
69	Health Literacy, Language, and Ethnicity-Related Factors in Newcomer Asthma Patients to Canada: A Qualitative Study. <i>Journal of Immigrant and Minority Health</i> , 2011, 13, 315-322.	1.6	52
70	Baseline characteristics and comorbidities in the CANadian REgistry for Pulmonary Fibrosis. <i>BMC Pulmonary Medicine</i> , 2019, 19, 223.	2.0	52
71	Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 409-418.	2.1	51
72	Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 366-370.	2.8	50

#	ARTICLE	IF	CITATIONS
73	Bronchial thermoplasty in asthma: 2-year follow-up using optical coherence tomography. <i>European Respiratory Journal</i> , 2015, 46, 859-862.	6.7	49
74	Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: A simulation study. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 908-915.e3.	2.9	48
75	Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. <i>Thorax</i> , 2008, 63, 962-967.	5.6	47
76	Impaired Sleep Quality in COPD Is Associated With Exacerbations. <i>Chest</i> , 2019, 156, 852-863.	0.8	47
77	Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study. <i>European Respiratory Journal</i> , 2019, 53, 1801257.	6.7	46
78	Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 149-158.	10.7	46
79	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. <i>Canadian Respiratory Journal</i> , 2016, 2016, 1-7.	1.6	45
80	The natural history of severe asthma and influences of early risk factors: a population-based cohort study. <i>Thorax</i> , 2016, 71, 267-275.	5.6	45
81	Identification and definition of asthma-COPD overlap: The CanCOLD study. <i>Respirology</i> , 2020, 25, 836-849.	2.3	45
82	Resource Use Study in COPD (RUSIC): A prospective Study to Quantify the Effects of COPD Exacerbations on Health Care Resource Use Among COPD Patients. <i>Canadian Respiratory Journal</i> , 2007, 14, 145-152.	1.6	44
83	Excess economic burden of comorbidities in COPD: a 15-year population-based study. <i>European Respiratory Journal</i> , 2017, 50, 1700393.	6.7	44
84	The Impact of Statin Drug Use on All-Cause Mortality in Patients With COPD. <i>Chest</i> , 2017, 152, 486-493.	0.8	43
85	B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. <i>BMC Pulmonary Medicine</i> , 2017, 17, 11.	2.0	43
86	Recognition and management of severe asthma: A Canadian Thoracic Society position statement. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2017, 1, 199-221.	0.5	42
87	Potential Severe Asthma Hidden in UK Primary Care. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1612-1623.e9.	3.8	42
88	Inhaled Corticosteroids and the Risk of Fractures in Older Adults. <i>Drug Safety</i> , 2008, 31, 409-414.	3.2	41
89	Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 63-78.	3.4	41
90	Complementary and alternative asthma treatments and their association with asthma control: a population-based study. <i>BMJ Open</i> , 2013, 3, e003360.	1.9	39

#	ARTICLE	IF	CITATIONS
91	Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 578-588.e2.	3.8	39
92	Individualized prediction of lung-function decline in chronic obstructive pulmonary disease. <i>Cmaj</i> , 2016, 188, 1004-1011.	2.0	38
93	Impact of a COPD comprehensive case management program on hospital length of stay and readmission rates. <i>International Journal of COPD</i> , 2017, Volume 12, 961-971.	2.3	38
94	International Severe Asthma Registry. <i>Chest</i> , 2020, 157, 805-814.	0.8	38
95	Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 3.	1.5	37
96	Introduction to precision medicine in COPD. <i>European Respiratory Journal</i> , 2019, 53, 1802460.	6.7	37
97	Cost-effectiveness of oral appliances in the treatment of obstructive sleep apnoea—hypopnoea. <i>Sleep and Breathing</i> , 2009, 13, 241-252.	1.7	36
98	A statistical method was used for the meta-analysis of tests for latent TB—in the absence of a gold standard, combining random-effect and latent-class methods to estimate test accuracy. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 257-269.	5.0	36
99	Biomarker Development in COPD. <i>Chest</i> , 2017, 151, 455-467.	0.8	36
100	Targeting lung attacks. <i>Thorax</i> , 2011, 66, 365-366.	5.6	35
101	Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: A 17-year experience. <i>BMC Neurology</i> , 2004, 4, 12.	1.8	34
102	Economic and Humanistic Burden of External Genital Warts. <i>Pharmacoeconomics</i> , 2012, 30, 1-16.	3.3	34
103	Asthma Is Associated With Subsequent Development of Inflammatory Bowel Disease: A Population-based Case—Control Study. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1405-1412.e3.	4.4	34
104	Excess medical costs in patients with asthma and the role of comorbidity. <i>European Respiratory Journal</i> , 2016, 48, 1584-1592.	6.7	33
105	A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma. <i>Journal of Asthma</i> , 2019, 56, 1334-1346.	1.7	33
106	The burden of exacerbations in mild asthma: a systematic review. <i>ERJ Open Research</i> , 2020, 6, 00359-2019.	2.6	33
107	Future Impact of Various Interventions on the Burden of COPD in Canada: A Dynamic Population Model. <i>PLoS ONE</i> , 2012, 7, e46746.	2.5	32
108	The effects of marijuana smoking on lung function in older people. <i>European Respiratory Journal</i> , 2019, 54, 1900826.	6.7	32

#	ARTICLE	IF	CITATIONS
109	Association between COPD exacerbations and lung function decline during maintenance therapy. <i>Thorax</i> , 2020, 75, 744-753.	5.6	32
110	Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 14-23.	5.6	32
111	The Association Between Rate and Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: An Application of a Joint Frailty-Logistic Model. <i>American Journal of Epidemiology</i> , 2016, 184, 681-689.	3.4	31
112	Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs. <i>European Respiratory Journal</i> , 2020, 55, 1902048.	6.7	31
113	The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given "as needed" in mild asthma: study protocols for two randomised controlled trials. <i>Trials</i> , 2017, 18, 12.	1.6	30
114	Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. <i>Journal of Asthma</i> , 2021, 58, 514-522.	1.7	30
115	A Cost-effectiveness Analysis of Propofol versus Midazolam for Procedural Sedation in the Emergency Department. <i>Academic Emergency Medicine</i> , 2008, 15, 32-39.	1.8	29
116	International severe asthma registry (ISAR): protocol for a global registry. <i>BMC Medical Research Methodology</i> , 2020, 20, 212.	3.1	29
117	Transparency in Decision Modelling: What, Why, Who and How?. <i>Pharmacoeconomics</i> , 2019, 37, 1355-1369.	3.3	28
118	Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma. <i>Journal of Asthma and Allergy</i> , 2019, Volume 12, 401-413.	3.4	28
119	Risk of Incident Chronic Obstructive Pulmonary Disease in Rheumatoid Arthritis: A Population-Based Cohort Study. <i>Arthritis Care and Research</i> , 2019, 71, 602-610.	3.4	28
120	Reconcilable Differences. <i>Chest</i> , 2004, 126, 1161-1168.	0.8	27
121	Is Surgical Fixation for Stress-Positive Unstable Ankle Fractures Cost Effective? Results of a Multicenter Randomized Control Trial. <i>Journal of Orthopaedic Trauma</i> , 2012, 26, 652-658.	1.4	27
122	Need for Speed: An Efficient Algorithm for Calculation of Single-Parameter Expected Value of Partial Perfect Information. <i>Value in Health</i> , 2013, 16, 438-448.	0.3	27
123	Predictors of inappropriate and excessive use of reliever medications in asthma: a 16-year population-based study. <i>BMC Pulmonary Medicine</i> , 2018, 18, 33.	2.0	27
124	Long-Term Trajectories of Mild Asthma in Adulthood and Risk Factors of Progression. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 2024-2032.e5.	3.8	27
125	Economic burden of multimorbidity in patients with severe asthma: a 20-year population-based study. <i>Thorax</i> , 2019, 74, 1113-1119.	5.6	27
126	Concurrent physician-diagnosed asthma and chronic obstructive pulmonary disease: A population study of prevalence, incidence and mortality. <i>PLoS ONE</i> , 2017, 12, e0173830.	2.5	27

#	ARTICLE	IF	CITATIONS
127	The added effect of comorbidity on health-related quality of life in patients with asthma. <i>Quality of Life Research</i> , 2015, 24, 2507-2517.	3.1	26
128	Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review. <i>Respirology</i> , 2017, 22, 61-70.	2.3	25
129	The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial. <i>European Respiratory Journal</i> , 2018, 51, 1701488.	6.7	25
130	Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. <i>Chest</i> , 2022, 161, 1320-1329.	0.8	25
131	Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma. <i>Allergology International</i> , 2018, 67, 266-272.	3.3	24
132	Current recommendations for the treatment of mild asthma. <i>Journal of Asthma and Allergy</i> , 2010, 3, 169.	3.4	23
133	The Need for Humanomics in the Era of Genomics and the Challenge of Chronic Disease Management. <i>Chest</i> , 2014, 146, 10-12.	0.8	23
134	Quality of Life and Asthma Symptom Control: Room for Improvement in Care and Measurement. <i>Value in Health</i> , 2015, 18, 1043-1049.	0.3	23
135	Has Asthma Medication Use Caught Up With the Evidence?. <i>Chest</i> , 2017, 151, 612-618.	0.8	23
136	Patterns of Biologics Utilization and Discontinuation Before and During Pregnancy in Women With Autoimmune Diseases: A Population-Based Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 979-986.	3.4	23
137	<p>Asthma impacts on workplace productivity in employed patients who are symptomatic despite background therapy: a multinational survey</p>. <i>Journal of Asthma and Allergy</i> , 2019, Volume 12, 183-194.	3.4	23
138	Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based cohort study. <i>BMJ Open</i> , 2019, 9, e023714.	1.9	23
139	Population-based case-finding to identify subjects with undiagnosed asthma or COPD. <i>European Respiratory Journal</i> , 2020, 55, 2000024.	6.7	23
140	The effect of weekly text-message communication on treatment completion among patients with latent tuberculosis infection: study protocol for a randomised controlled trial (WelTel LTBI). <i>BMJ Open</i> , 2014, 4, e004362.	1.9	22
141	Saving in medical costs by achieving guideline-based asthma symptom control: a population-based study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 371-377.	5.7	22
142	Testing the External Validity of a Discrete Choice Experiment Method: An Application to Latent Tuberculosis Infection Treatment. <i>Value in Health</i> , 2017, 20, 969-975.	0.3	22
143	A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease. <i>Value in Health</i> , 2017, 20, 152-162.	0.3	22
144	Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213023.	0.9	22

#	ARTICLE	IF	CITATIONS
145	The projected economic and health burden of sub-optimal asthma control in Canada. <i>Respiratory Medicine</i> , 2018, 138, 7-12.	2.9	22
146	Characterizing undiagnosed chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>Respiratory Research</i> , 2018, 19, 26.	3.6	22
147	Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 266-271.e2.	2.9	22
148	Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1202-1216.e23.	3.8	22
149	Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β_2 -agonists for adults with asthma. <i>Respiratory Medicine</i> , 2018, 143, 82-90.	2.9	21
150	Predicting Severe Chronic Obstructive Pulmonary Disease Exacerbations. Developing a Population Surveillance Approach with Administrative Data. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1069-1076.	3.2	21
151	Performance Characteristics of Spirometry With Negative Bronchodilator Response and Methacholine Challenge Testing and Implications for Asthma Diagnosis. <i>Chest</i> , 2020, 158, 479-490.	0.8	21
152	Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?. <i>European Respiratory Journal</i> , 2021, 57, 2002122.	6.7	21
153	The association between previous and future severe exacerbations of chronic obstructive pulmonary disease: Updating the literature using robust statistical methodology. <i>PLoS ONE</i> , 2018, 13, e0191243.	2.5	21
154	Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study. <i>BMJ Open</i> , 2017, 7, e015108.	1.9	20
155	Comparative outcomes of leukotriene receptor antagonists and long-acting β_2 -agonists as add-on therapy in asthmatic patients: A population-based study. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 63-69.	2.9	19
156	Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries. <i>Emerging Infectious Diseases</i> , 2019, 25, 661-671.	4.3	19
157	COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry. <i>PLoS ONE</i> , 2016, 11, e0161129.	2.5	19
158	Interaction effect of psychological distress and asthma control on productivity loss?. <i>European Respiratory Journal</i> , 2015, 45, 1557-1565.	6.7	18
159	Assessing beliefs and risk perceptions on smoking and smoking cessation in immigrant Chinese adult smokers residing in Vancouver, Canada: a cross-sectional study. <i>BMJ Open</i> , 2015, 5, e006435-e006435.	1.9	18
160	Airway diseases and health literacy (HL) measurement tools: A systematic review to inform respiratory research and practice. <i>Patient Education and Counseling</i> , 2018, 101, 596-618.	2.2	18
161	Novel Blood-based Transcriptional Biomarker Panels Predict the Late-Phase Asthmatic Response. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 450-462.	5.6	18
162	A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. <i>Respiratory Research</i> , 2020, 21, 322.	3.6	18

#	ARTICLE	IF	CITATIONS
163	Health Care Costs Associated with Acute Asthma: A Prospective Economic Analysis. Canadian Respiratory Journal, 1999, 6, 521-525.	1.6	17
164	Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial. Trials, 2016, 17, 502.	1.6	17
165	The neglected burden of tuberculosis disease among health workers: a decade-long cohort study in South Africa. BMC Infectious Diseases, 2017, 17, 547.	2.9	17
166	<p>The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline</p>. International Journal of COPD, 2020, Volume 15, 1909-1918.	2.3	17
167	Moving beyond AUC: decision curve analysis for quantifying net benefit of risk prediction models. European Respiratory Journal, 2021, 58, 2101186.	6.7	17
168	Costs and Health Outcomes Associated With Primary vs Secondary Care After an Asthma-Related Hospitalization. Chest, 2013, 144, 428-435.	0.8	16
169	Dispensation of long-acting Å agonists with or without inhaled corticosteroids, and risk of asthma-related hospitalisation: a population-based study. Thorax, 2014, 69, 328-334.	5.6	16
170	History of Asthma in Patients with Chronic Obstructive Pulmonary Disease. A Comparative Study of Economic Burden. Annals of the American Thoracic Society, 2016, 13, 188-196.	3.2	16
171	Influences of Socioeconomic Status on Costs of Asthma Under Universal Health Coverage. Medical Care, 2016, 54, 789-795.	2.4	16
172	Do cost savings from reductions in nosocomial infections justify additional costs of single-bed rooms in intensive care units? A simulation case study. Journal of Critical Care, 2016, 31, 194-200.	2.2	16
173	Ten-year trends in direct costs of asthma: a population-based study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 291-299.	5.7	16
174	Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study. Archives of Osteoporosis, 2018, 13, 116.	2.4	16
175	Phenotyping COPD exacerbations using imaging and blood-based biomarkers. International Journal of COPD, 2018, Volume 13, 217-229.	2.3	16
176	<p>Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada</p>. International Journal of COPD, 2019, Volume 14, 2003-2013.	2.3	16
177	Making sense of cost-effectiveness analyses in respiratory medicine: a practical guide for non-health economists. European Respiratory Journal, 2019, 53, 1801816.	6.7	16
178	The Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and the Heterogeneity of Risk Factors in the Canadian Population: Results from the Canadian Obstructive Lung Disease (COLD) Study. International Journal of COPD, 2021, Volume 16, 305-320.	2.3	16
179	Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 20-27.	3.2	16
180	Artificial neural networks in prediction of bone density among post-menopausal women. Journal of Endocrinological Investigation, 2005, 28, 425-431.	3.3	15

#	ARTICLE	IF	CITATIONS
181	Cost-Effectiveness of LTBI Treatment for TB Contacts in British Columbia. <i>Value in Health</i> , 2008, 11, 842-852.	0.3	15
182	Reliability studies of diagnostic tests are not using enough observers for robust estimation of interobserver agreement: a simulation study. <i>Journal of Clinical Epidemiology</i> , 2008, 61, 722-727.	5.0	15
183	Empowering pharmacists in asthma management through interactive SMS (EmPhAsIS): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 488.	1.6	15
184	Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada. <i>PLoS ONE</i> , 2017, 12, e0186778.	2.5	15
185	An Individualized Prediction Model for Long-term Lung Function Trajectory and Risk of COPD in the General Population. <i>Chest</i> , 2020, 157, 547-557.	0.8	15
186	Looking at the COPD spectrum through "PRISM". <i>European Respiratory Journal</i> , 2020, 55, 1902217.	6.7	15
187	The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK. <i>Respiratory Medicine</i> , 2020, 171, 106079.	2.9	15
188	The impact of comorbidities on productivity loss in asthma patients. <i>Respiratory Research</i> , 2016, 17, 106.	3.6	14
189	Culturally Specific Evaluation of Inhaler Techniques in Asthma. <i>Respiratory Care</i> , 2016, 61, 1588-1596.	1.6	14
190	Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. <i>Chest</i> , 2019, 156, 887-895.	0.8	14
191	Cost-effectiveness of implementing objective diagnostic verification of asthma in the United States. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1367-1377.e4.	2.9	14
192	C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations. <i>PLoS ONE</i> , 2017, 12, e0174063.	2.5	14
193	Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study. <i>Respiratory Research</i> , 2020, 21, 118.	3.6	13
194	Barriers and Enablers to Objective Testing for Asthma and COPD in Primary Care. <i>Chest</i> , 2022, 161, 888-905.	0.8	13
195	Impact of Socioeconomic Status on Adult Patients with Asthma: A Population-Based Cohort Study from UK Primary Care. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1375-1388.	3.4	13
196	A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net benefit framework. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1172-1180.	1.9	12
197	Low-Molecular-Weight Heparin Versus Unfractionated Heparin for Prophylaxis of Venous Thromboembolism in Medicine Patients—A Pharmacoeconomic Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 454-465.	1.7	12
198	The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis - a case study of pharmacotherapies for moderate to severe COPD. <i>Cost Effectiveness and Resource Allocation</i> , 2014, 12, 8.	1.5	12

#	ARTICLE	IF	CITATIONS
199	COST-effectiveness of salmeterol/fluticasone propionate combination (Advair [®]) in uncontrolled asthma in Canada. <i>Respiratory Medicine</i> , 2014, 108, 1292-1302.	2.9	12
200	Predictors of hospitalization of tuberculosis patients in Montreal, Canada: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2016, 16, 679.	2.9	12
201	Heterogeneity in the respiratory symptoms of patients with mild-to-moderate COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 3983-3995.	2.3	12
202	Model-Based ROC Curve: Examining the Effect of Case Mix and Model Calibration on the ROC Plot. <i>Medical Decision Making</i> , 2022, 42, 487-499.	2.4	12
203	Canadian Thoracic Society Asthma Committee Commentary on Long-Acting Beta-2 Agonist Use for Asthma in Canada. <i>Canadian Respiratory Journal</i> , 2010, 17, 57-58.	1.6	11
204	Level of Asthma Controller Therapy Before Admission to the Hospital. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 877-883.	3.8	11
205	The COPD Assessment Test. <i>Chest</i> , 2016, 150, 1069-1079.	0.8	11
206	Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis. <i>American Journal of Kidney Diseases</i> , 2019, 73, 39-50.	1.9	11
207	Excess Productivity Costs of Systemic Lupus Erythematosus, Systemic Sclerosis, and Sjögren's Syndrome: A General Population-Based Study. <i>Arthritis Care and Research</i> , 2019, 71, 142-154.	3.4	11
208	A patient decision aid for mild asthma: Navigating a new asthma treatment paradigm. <i>Respiratory Medicine</i> , 2022, 201, 106568.	2.9	11
209	Preferred skeletal site for osteoporosis screening in high-risk populations. <i>Public Health</i> , 2006, 120, 863-871.	2.9	10
210	An Ounce of Prevention Is Worth a Pound of Cure: A Cost-Effectiveness Analysis of Incidentally Detected Aneurysms in Functional MRI Research. <i>Value in Health</i> , 2010, 13, 761-769.	0.3	10
211	Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes. <i>Pharmacoeconomics</i> , 2014, 32, 995-1004.	3.3	10
212	Incremental direct medical costs of systemic lupus erythematosus patients in the years preceding diagnosis: A general population-based study. <i>Lupus</i> , 2018, 27, 1247-1258.	1.6	10
213	Development and Validation of the Evaluation Platform in COPD (EPIC): A Population-Based Outcomes Model of COPD for Canada. <i>Medical Decision Making</i> , 2019, 39, 152-167.	2.4	10
214	<p>Development and Pretesting of a New Functional-Based Health Literacy Measurement Tool for Chronic Obstructive Pulmonary Disease (COPD) and Asthma Management</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 613-625.	2.3	10
215	A Quantitative Benefit-Risk Analysis of Isoniazid for Treatment of Latent Tuberculosis Infection Using Incremental Benefit Framework. <i>Value in Health</i> , 2013, 16, 66-75.	0.3	9
216	Exploring the Potential Cost-Effectiveness of Patient Decision Aids for Use in Adults with Obstructive Sleep Apnea. <i>Medical Decision Making</i> , 2015, 35, 671-682.	2.4	9

#	ARTICLE	IF	CITATIONS
217	Attitude to health risk in the Canadian population: a cross-sectional survey. <i>CMAJ Open</i> , 2016, 4, E284-E291.	2.4	9
218	Stability of Asthma Symptom Control in a Longitudinal Study of Mild-Moderate Asthmatics. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1663-1670.e5.	3.8	9
219	Work productivity loss in mild to moderate COPD: lessons learned from the CanCOLD study. <i>European Respiratory Journal</i> , 2017, 50, 1701154.	6.7	9
220	The impact of a history of asthma on long-term outcomes of people with newly diagnosed chronic obstructive pulmonary disease: A population study. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 835-843.	2.9	9
221	A pilot randomized controlled trial on the impact of text messaging check-ins and a web-based asthma action plan versus a written action plan on asthma exacerbations. <i>Journal of Asthma</i> , 2019, 56, 897-909.	1.7	9
222	Probabilistic Return-on-Investment Analysis of Single-Family Versus Open-Bay Rooms in Neonatal Intensive Care Units—Synthesis and Evaluation of Early Evidence on Nosocomial Infections, Length of Stay, and Direct Cost of Care. <i>Journal of Intensive Care Medicine</i> , 2019, 34, 115-125.	2.8	9
223	Impact of the 13-valent pneumococcal conjugate vaccine on acute otitis media and acute sinusitis epidemiology in British Columbia, Canada. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2419-2427.	3.0	9
224	Current and emerging treatments for severe asthma. <i>Journal of Thoracic Disease</i> , 2015, 7, E522-5.	1.4	9
225	Pulmonary function testing in the Emergency Department and medications prescribed at discharge: results of the Multinational Acute asthma Management, Burden, and Outcomes (MAMBO) study. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2010, 19, 155-162.	2.3	8
226	TWO-LEVEL RESAMPLING AS A NOVEL METHOD FOR THE CALCULATION OF THE EXPECTED VALUE OF SAMPLE INFORMATION IN ECONOMIC TRIALS. <i>Health Economics (United Kingdom)</i> , 2013, 22, 877-882.	1.7	8
227	Does Culture or Illness Change a Smoker's Perspective on Cessation?. <i>American Journal of Health Behavior</i> , 2014, 38, 657-667.	1.4	8
228	The Emerging Role of Health Literacy in Chronic Disease Management: The Response to a Call for Action in Canada. <i>Population Health Management</i> , 2016, 19, 230-231.	1.7	8
229	Triple therapy in a single inhaler: a new option for uncontrolled asthma. <i>Lancet, The</i> , 2019, 394, 1690-1692.	13.7	8
230	A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions. <i>Value in Health</i> , 2019, 22, 1070-1082.	0.3	8
231	Socioeconomic status at diagnosis influences the incremental direct medical costs of systemic lupus erythematosus: A longitudinal population-based study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 77-83.	3.4	8
232	Asthma and COPD patients' perceived link between health literacy core domains and self-management of their condition. <i>Patient Education and Counseling</i> , 2020, 103, 1415-1421.	2.2	8
233	Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. <i>Drug Safety</i> , 2021, 44, 467-478.	3.2	8
234	Trends in oral corticosteroids use in severe asthma: a 14-year population-based study. <i>Respiratory Research</i> , 2021, 22, 103.	3.6	8

#	ARTICLE	IF	CITATIONS
235	Personalising add-on treatment with inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a benefit-harm modelling study. <i>The Lancet Digital Health</i> , 2021, 3, e644-e653.	12.3	8
236	The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada. <i>Allergy, Asthma and Clinical Immunology</i> , 2021, 17, 108.	2.0	8
237	Chronic Disease Management: A Proving Ground for Health Literacy. <i>Population Health Management</i> , 2014, 17, 321-323.	1.7	7
238	One-year outcomes of inhaled controller therapies added to systemic corticosteroids after asthma-related hospital discharge. <i>Respiratory Medicine</i> , 2015, 109, 320-328.	2.9	7
239	Enumerateblood - an R package to estimate the cellular composition of whole blood from Affymetrix Gene ST gene expression profiles. <i>BMC Genomics</i> , 2017, 18, 43.	2.8	7
240	Mortality and acute exacerbation of COPD: a pilot study on the influence of myocardial injury. <i>European Respiratory Journal</i> , 2017, 49, 1700096.	6.7	7
241	Asthma control and productivity loss in those with work-related asthma: A population-based study. <i>Journal of Asthma</i> , 2017, 54, 537-542.	1.7	7
242	Patients as research partners in chronic obstructive pulmonary disease and asthma research: Priorities, challenges and recommendations from asthma and COPD patients. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2018, 2, 138-146.	0.5	7
243	Between-Visit Variability in FEV1 as a Diagnostic Test for Asthma in Adults. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1039-1046.	3.2	7
244	Direct costs of overdiagnosed asthma: a longitudinal, population-based cohort study in British Columbia, Canada. <i>BMJ Open</i> , 2019, 9, e031306.	1.9	7
245	Effects of β_2 -Adrenergic Agonists on Risk of Parkinson's Disease in COPD: A Population-Based Study. <i>Pharmacotherapy</i> , 2020, 40, 408-415.	2.6	7
246	Cost Effectiveness of Case Detection Strategies for the Early Detection of COPD. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 203-215.	2.1	7
247	A conceptual model of functional health literacy to improve chronic airway disease outcomes. <i>BMC Public Health</i> , 2021, 21, 252.	2.9	7
248	Perceived Barriers to Asthma Therapy in Ethno-Cultural Communities: The Role of Culture, Beliefs and Social Support. <i>Health</i> , 2017, 09, 1029-1046.	0.3	7
249	Optimal decision criterion for detecting change in bone mineral density during serial monitoring: A Bayesian approach. <i>Osteoporosis International</i> , 2008, 19, 1589-96.	3.1	6
250	Heteroscedastic Regression Analysis of Factors Affecting BMD Monitoring. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1842-1849.	2.8	6
251	Technical Note: Acceptability Curves Could Be Misleading When Correlated Strategies Are Compared. <i>Medical Decision Making</i> , 2008, 28, 306-307.	2.4	6
252	Heterogeneity's ruses: the neglected role of between-individual variability in longitudinal studies of COPD exacerbations. <i>Thorax</i> , 2014, 69, 1043-1044.	5.6	6

#	ARTICLE	IF	CITATIONS
253	Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype. Expert Review of Clinical Pharmacology, 2018, 11, 669-676.	3.1	6
254	Precision health: treating the individual patient with chronic obstructive pulmonary disease. Medical Journal of Australia, 2019, 210, 424-428.	1.7	6
255	Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis. Immunotherapy, 2019, 11, 1491-1505.	2.0	6
256	Are COPD Prescription Patterns Aligned with Guidelines? Evidence from a Canadian Population-Based Study. International Journal of COPD, 2021, Volume 16, 751-759.	2.3	6
257	An Integrated Framework to Conceptualize and Develop the Vancouver Airways Health Literacy Tool (VAHLT). International Journal of Environmental Research and Public Health, 2021, 18, 8646.	2.6	6
258	Derivation and validation of the UCAP-Q case-finding questionnaire to detect undiagnosed asthma and COPD. European Respiratory Journal, 2022, 60, 2103243.	6.7	6
259	The Value of Bayes Theorem in the Interpretation of Subjective Diagnostic Findings: What Can We Learn from Agreement Studies?. Medical Decision Making, 2007, 27, 735-743.	2.4	5
260	A New Approach for Quantifying Change and Test Precision in Bone Densitometry. Journal of Clinical Densitometry, 2007, 10, 365-369.	1.2	5
261	Post-hospital syndrome in adults with asthma: a case-crossover study. Allergy, Asthma and Clinical Immunology, 2013, 9, 49.	2.0	5
262	Incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods. Trials, 2014, 15, 201.	1.6	5
263	Do community demographics, environmental characteristics and access to care affect risks of developing ACOS and mortality in people with asthma?. European Respiratory Journal, 2017, 50, 1700644.	6.7	5
264	The diagnostic performance of patient symptoms in screening for COPD. Respiratory Research, 2018, 19, 147.	3.6	5
265	Lowering the P Value Threshold. JAMA - Journal of the American Medical Association, 2019, 321, 1532.	7.4	5
266	Vitamin D in the prevention of exacerbations of asthma in preschoolers (DIVA): protocol for a multicentre randomised placebo-controlled triple-blind trial. BMJ Open, 2019, 9, e033075.	1.9	5
267	Bridging the gap: Key informants' perspectives on patient barriers in asthma and COPD self-management and possible solutions. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 106-114.	0.5	5
268	Asthma exacerbations and worsenings in patients aged 18-75 years with add-on tiotropium treatment. Npj Primary Care Respiratory Medicine, 2020, 30, 38.	2.6	5
269	Costs of Workplace Productivity Loss in Patients with Connective Tissue Disease-associated Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1077-1084.	3.2	5
270	Healthcare system encounters before COPD diagnosis: a registry-based longitudinal cohort study. Thorax, 2020, 75, 108-115.	5.6	5

#	ARTICLE	IF	CITATIONS
271	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. <i>Respiratory Research</i> , 2021, 22, 202.	3.6	5
272	Assessing factors influencing smoking and smoking cessation within Chinese communities in the Greater Vancouver Area: A qualitative exploratory study. <i>Tobacco Prevention and Cessation</i> , 2020, 6, 1-14.	0.4	5
273	Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease. <i>Annals of the American Thoracic Society</i> , 2022, 19, 962-970.	3.2	5
274	A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies. <i>BMC Pulmonary Medicine</i> , 2022, 22, 148.	2.0	5
275	Long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2014, , .	2.8	4
276	Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation. <i>Biomarker Insights</i> , 2017, 12, 117727191773030.	2.5	4
277	Asthma in low-income and middle-income countries: an urgent call to action. <i>Thorax</i> , 2018, 73, 898-899.	5.6	4
278	Effect of short-term oral prednisone therapy on blood gene expression: a randomised controlled clinical trial. <i>Respiratory Research</i> , 2019, 20, 176.	3.6	4
279	Cholinergic synapse pathway gene polymorphisms associated with allergen-induced late asthmatic responses. <i>ERJ Open Research</i> , 2019, 5, 00107-2019.	2.6	4
280	Treatment Initiation in Patients with Interstitial Lung Disease in Canada. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1661-1668.	3.2	4
281	Specialist Care in Individuals with Asthma Who Required Hospitalization: A Retrospective Population-Based Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3686-3696.	3.8	4
282	Benefit-harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease. <i>Thorax</i> , 2022, 77, 1079-1087.	5.6	4
283	Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease. <i>Chest</i> , 2022, 161, 1594-1597.	0.8	4
284	Clinical relevance of rheumatoid factor and anti-citrullinated peptides in fibrotic interstitial lung disease. <i>Respirology</i> , 0, , .	2.3	4
285	Disease burden in individuals with symptomatic undiagnosed asthma or COPD. <i>Respiratory Medicine</i> , 2022, 200, 106917.	2.9	4
286	Airway diseases and inflammatory bowel diseases: is it something in the air (pollution)?. <i>European Respiratory Journal</i> , 2015, 46, 287-288.	6.7	3
287	Modifying the trajectory of asthma—are there lessons from the use of biologics in rheumatology?. <i>Lancet, The</i> , 2017, 389, 1082-1084.	13.7	3
288	Crowdfunding for respiratory research: a new frontier for patient and public engagement?. <i>European Respiratory Journal</i> , 2017, 50, 1701333.	6.7	3

#	ARTICLE	IF	CITATIONS
289	Improving precision in the prediction of asthma exacerbations. <i>Lancet Respiratory Medicine</i> , 2017, 5, 539-540.	10.7	3
290	Relative impact characteristic curve: a graphical tool to visualize and quantify the clinical utility and population-level consequences of implementing markers. <i>Annals of Epidemiology</i> , 2018, 28, 717-723.e3.	1.9	3
291	A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada. <i>Vaccine</i> , 2022, 40, 1047-1053.	3.8	3
292	Uncertainty and the Value of Information in Risk Prediction Modeling. <i>Medical Decision Making</i> , 2022, 42, 661-671.	2.4	3
293	The importance of measuring asthma control in emerging economies [Editorial]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 254-254.	1.2	2
294	The asthma control in daily practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 907-909.	5.7	2
295	The Impact of Care Specialty on Survival-Adjusted Medical Costs of COPD Patients After a Hospitalization: a longitudinal analysis. <i>Journal of General Internal Medicine</i> , 2018, 33, 1528-1535.	2.6	2
296	The reporting of observational studies of drug effectiveness and safety: recommendations to extend existing guidelines. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-8.	2.4	2
297	The economics of precision health: preventing air pollution-induced exacerbation in asthma. <i>ERJ Open Research</i> , 2021, 7, 00790-2020.	2.6	2
298	Pan-Canadian standards for severe asthma in electronic medical records. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2021, 5, 391-399.	0.5	2
299	Long-Term Natural History of Severe Asthma Exacerbations and Their Impact on the Disease Course. <i>Annals of the American Thoracic Society</i> , 2022, 19, 907-915.	3.2	2
300	Sample size requirements for bone density precision assessments and effect on patient categorization: A Monte Carlo simulation study. <i>Bone</i> , 2007, 41, 679-684.	2.9	1
301	Letter to the Editor. <i>Vaccine</i> , 2008, 26, 5244.	3.8	1
302	Response to "Marginal Costs of Hospital-Acquired Conditions: Information for Priority-Setting for Patient Safety Programmes and Research"™, Jackson et al., <i>Journal of Health Services Research & Policy</i> 2011;16:141-6. <i>Journal of Health Services Research and Policy</i> , 2012, 17, 127-127.	1.7	1
303	The "Lost NNT" can be used to represent uncertainty surrounding number needed to treat. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 863-868.	5.0	1
304	The Humanistic And Economic Impact Of Following Evidence-Based Asthma Controller Therapy: A Simulation Study. <i>Value in Health</i> , 2013, 16, A235.	0.3	1
305	COPD. <i>Chest</i> , 2015, 147, 868-869.	0.8	1
306	Emerging interleukin receptor antagonists for the treatment of asthma. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 275-283.	2.4	1

#	ARTICLE	IF	CITATIONS
307	Asthma patient education, the overlooked aspect of disease management. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 43-45.	0.5	1
308	Asthma is not associated with the need for surgery in Crohn's disease when controlling for smoking status: a population-based cohort study. Clinical Epidemiology, 2018, Volume 10, 831-840.	3.0	1
309	The Challenges and Opportunities of Maximizing the Benefits of Severe Asthma Registries. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1469-1470.	3.8	1
310	Extent, trends, and determinants of controller/reliever balance in mild asthma: a 14-year population-based study. Respiratory Research, 2019, 20, 44.	3.6	1
311	<p>Patient-Reported Outcome Measures (PROMs) to Support Adherence to Falls Prevention Clinic Recommendations: A Qualitative Study</p>. Patient Preference and Adherence, 2020, Volume 14, 2105-2121.	1.8	1
312	A threshold-free summary index for quantifying the capacity of covariates to yield efficient treatment rules. Statistics in Medicine, 2020, 39, 1362-1373.	1.6	1
313	Targeted management of severe asthma: Developing a Canadian approach. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 124-132.	0.5	1
314	Effects of long-term inhaled corticosteroid treatment on fragility fractures in older women: the Manitoba BMD registry study. Osteoporosis International, 2020, 31, 1155-1162.	3.1	1
315	A Benefit-Harm Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. SSRN Electronic Journal, 0, , .	0.4	1
316	Asthma control in preschoolers: a strong predictor of long-term morbidity. , 2019, , .		1
317	The Hidden and Unchecked Judgement Calls When Using Exacerbation History for Managing COPD. Archivos De Bronconeumologia, 2022, 58, 629-631.	0.8	1
318	Achieving asthma control:Providing a framework forclinicians. Annals of Thoracic Medicine, 2016, 11, 1.	1.8	1
319	Development of a conceptual model of childhood asthma to inform asthma prevention policies. BMJ Open Respiratory Research, 2021, 8, e000881.	3.0	1
320	A personalized biomedical risk assessment infographic for people who smoke with COPD: a qualitative study. Addiction Science & Clinical Practice, 2022, 17, 1.	2.6	1
321	External validation of lung function predictions in real-world cohorts of COPD. Respiratory Medicine, 2022, 198, 106859.	2.9	1
322	Review: Magnesium sulfate is effective for severe acute asthma treated in the emergency department. ACP Journal Club, 1999, 131, 36.	0.1	1
323	Cost-optimisation of screening for latent tuberculosis in close contacts. European Respiratory Journal, 2006, 28, 1285-1285.	6.7	0
324	Asthma guidelines: Global to local. Annals of Thoracic Medicine, 2009, 4, 161.	1.8	0

#	ARTICLE	IF	CITATIONS
325	Asthma Control In A Random Sample Of Canadian Asthma Patients. , 2012, , .		0
326	Use Of Complementary And Alternative Therapies In Patients With Asthma: Preliminary Results From A Prospective Study. , 2012, , .		0
327	Safety Of Long-Acting Beta Agonists (LABA) With Or Without Inhaled Corticosteroids In Asthma. , 2012, , .		0
328	Predicting Lung Transplant Waitlist Survival with the Lung Allocation Score in British Columbia, Canada. Journal of Heart and Lung Transplantation, 2013, 32, S168-S169.	0.6	0
329	Exacerbations in non-COPD patients: truth or myth? authors' response. Thorax, 2014, 69, 1050.2-1051.	5.6	0
330	Elevated risk of chronic obstructive pulmonary disease in systemic lupus erythematosus: a population-based study. Arthritis Research and Therapy, 2014, 16, A34.	3.5	0
331	Author response to commentary on article "Intensive care unit-acquired infections: It is not only about the number of patients per room". Journal of Critical Care, 2016, 34, 124.	2.2	0
332	Less chaos in the prognosis of asthma-chronic obstructive lung disease overlap. Lancet Respiratory Medicine, 2016, 4, 421-422.	10.7	0
333	Response. Chest, 2018, 153, 578-579.	0.8	0
334	Long-acting beta ₂ -agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease. The Cochrane Library, 0, , .	2.8	0
335	History of respiratory medicine at University of British Columbia. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 53-57.	0.5	0
336	Understanding resource utilization and mortality in COPD to support policy making: A microsimulation study. PLoS ONE, 2020, 15, e0236559.	2.5	0
337	Avoiding immortal time bias in observational studies. European Respiratory Journal, 2020, 55, 1902494.	6.7	0
338	Response. Chest, 2020, 157, 738-739.	0.8	0
339	Asthma Is Not Associated With the Need for Surgery in Crohn's Disease When Controlling for Smoking Status: A Population-Based Cohort Study. American Journal of Gastroenterology, 2017, 112, S1476.	0.4	0
340	Drivers of respiratory symptoms in COPD patients. , 2018, , .		0
341	The discriminatory capacity of symptoms to distinguish undiagnosed COPD from non-COPD. , 2018, , .		0
342	Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
343	Late Breaking Abstract - Asthma control in preschool and subsequent disease remission. , 2019, , .		0
344	Effect of COPD exacerbations on early lung function decline under maintenance therapy: blood eosinophil count asbiomarker. , 2019, , .		0
345	Effects of Regular Use of ÅŒ2-Adrenergic Receptor Agonists on the Risk of Parkinsonâ€™s Disease in Patients with COPD. , 2019, , .		0
346	Testing Clinical Prediction Modelsâ€™Reply. JAMA - Journal of the American Medical Association, 2020, 324, 2000.	7.4	0
347	Validation of the 4C prediction models to inform care for patients with COVID-19: final steps towards clinical application. Thorax, 2022, 77, 536-536.	5.6	0
348	Asthma. Clinical Evidence, 2003, , 1616-40.	0.2	0